ICT, Lasa realise success in Favipiravir drug synthesis

The partnership is looking at manufacturing close to 10,000 doses to begin with

ICT, Lasa, Favipiravir, Dr Omkar Herlekar, Vikas N Telvekar, Antiviral

Veterinary API Major, Lasa Supergenerics and Institute of Chemical Technology had come together in the month of March 2020 in effort to bring the antiviral to the market as a promising therapy to fight the ongoing Covid-19 pandemic.

Commenting on the development, Dr Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said, “Efforts over the last few months has brought success and we are looking to manufacture close to 10,000 doses to begin with and in the meanwhile also apply for the drug licence with competent authorities and continue to seek strategic private investments or Government aid. Our move into human steroid API is in line with the organisations inherent strengths and objectives to diversify.”

Commenting on the antivirals successful synthesis, Prof Vikas N Telvekar, ICT, Mumbai, said, “We are happy to share with you that the Favipiravir molecule has been successfully synthesised in the ICT laboratory on a lab scale and further pilot plan scale up is required.”

Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease (COVID-2019). It possesses activity against many RNA viruses.

Recently in its Q4 results, the company reported a healthy increase in its PAT to Rs 3.63 cr for FY20, as compared to a loss of Rs 12.04 cr in the corresponding period last fiscal.

Share